Ftse Mib
34.177,65
0,08%
DAX
18.537,20
0,27%
S&P 500
5.187,67
0,00%
NASDAQ
16.302,76
-0,18%
Bitcoin
61.385,52
0,32%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Prelude Therapeutics Inc (PRLD) Prelude Therapeutics Inc (PRLD) Notizie

PRLD

Prelude Therapeutics (PRLD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRLD
DataOraFonteTitoloSimboloCompagnia
07/05/202413:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
07/05/202413:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202413:01GlobeNewswire Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
06/05/202422:24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/04/202422:35GlobeNewswire Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202422:45GlobeNewswire Inc.Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202400:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
29/02/202422:05GlobeNewswire Inc.Prelude Therapeutics to Participate in Barclays Global Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202423:22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRLDPrelude Therapeutics Inc
15/02/202422:05GlobeNewswire Inc.Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/02/202422:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
11/12/202315:34GlobeNewswire Inc.Prelude Therapeutics Announces $25 Million Private PlacementNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321:10GlobeNewswire Inc.Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321:05GlobeNewswire Inc.Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
14/10/202318:30GlobeNewswire Inc.Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference NASDAQ:PRLDPrelude Therapeutics Inc
29/08/202314:30GlobeNewswire Inc.Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberNASDAQ:PRLDPrelude Therapeutics Inc
03/08/202314:00GlobeNewswire Inc.Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
21/06/202322:17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRLDPrelude Therapeutics Inc
21/06/202322:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRLDPrelude Therapeutics Inc
31/05/202314:30GlobeNewswire Inc.Prelude Therapeutics To Participate in Jefferies Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
24/05/202322:55Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PRLDPrelude Therapeutics Inc
18/05/202313:00GlobeNewswire Inc.Prelude Therapeutics Announces Pricing of Public OfferingNASDAQ:PRLDPrelude Therapeutics Inc
17/05/202322:08GlobeNewswire Inc.Prelude Therapeutics Announces Launch of Proposed Public OfferingNASDAQ:PRLDPrelude Therapeutics Inc
08/05/202314:30GlobeNewswire Inc.Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations UpdateNASDAQ:PRLDPrelude Therapeutics Inc
08/05/202314:12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PRLDPrelude Therapeutics Inc
28/04/202315:47Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PRLDPrelude Therapeutics Inc
28/04/202315:42Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PRLDPrelude Therapeutics Inc
28/04/202314:47Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PRLDPrelude Therapeutics Inc
27/04/202314:30GlobeNewswire Inc.Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in MayNASDAQ:PRLDPrelude Therapeutics Inc
18/04/202322:01Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:PRLDPrelude Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRLD

La tua Cronologia

BIT
BPE
Bper Banca
BIT
NEXI
Nexi S.p.A
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
LDO
Leonardo
BIT
ENEL
Enel
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
FCT
Fincantieri
BIT
TRN
Terna Trasmissione Elett...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network